GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kronos Bio Inc (NAS:KRON) » Definitions » Degree of Operating Leverage

KRON (Kronos Bio) Degree of Operating Leverage : -2.51 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Kronos Bio Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Kronos Bio's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -2.51. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Kronos Bio's Degree of Operating Leverage or its related term are showing as below:

KRON's Degree of Operating Leverage is ranked better than
81.21% of 878 companies
in the Biotechnology industry
Industry Median: -0.025 vs KRON: -2.51

Kronos Bio Degree of Operating Leverage Historical Data

The historical data trend for Kronos Bio's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kronos Bio Degree of Operating Leverage Chart

Kronos Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial - - - - -0.81

Kronos Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.13 -0.26 -0.81 -2.51

Competitive Comparison of Kronos Bio's Degree of Operating Leverage

For the Biotechnology subindustry, Kronos Bio's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kronos Bio's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kronos Bio's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Kronos Bio's Degree of Operating Leverage falls into.


;
;

Kronos Bio Degree of Operating Leverage Calculation

Kronos Bio's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -50.598 (Mar. 2025) / -107.916 (Mar. 2024) - 1 )/( 9.192 (Mar. 2025) / 7.587 (Mar. 2024) - 1 )
=-0.5311/0.2115
=-2.51***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Kronos Bio  (NAS:KRON) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Kronos Bio Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Kronos Bio's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Kronos Bio Business Description

Industry
Traded in Other Exchanges
N/A
Address
1300 So. El Camino Real, Suite 400, San Mateo, CA, USA, 94402
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
Executives
Norbert W Bischofberger director, 10 percent owner, officer: President & CEO 333 LAKESIDE DR, C/O GILEAD SCIENCES, INC., FOSTER CITY CA 94404
Jorge Dimartino officer: Chief Medical Officer & VP C/O KRONOS BIO, INC., 1300 S, SAN MATEO CA 94402
Christopher Dinsmore officer: Chief Scientific Officer C/O KRONOS BIO, INC., 1300 EL CAMINO REAL, STE. 300, SAN MATEO CA 94402
Barbara Kosacz officer: COO & General Counsel 3175 HANOVER STREET, PALO ALTO CA 94304
Sandra A. Gardiner officer: Interim CFO CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Yasir B. Al-wakeel officer: Chief Financial Officer MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Roger D Dansey director 21823 30TH DRIVE SE, BOTHELL WA 98021
Katherine V Stultz director C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Backer Marianne De director 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jakob Loven director C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Taiyin Yang director 2631 HANOVER STREET, PALO ALTO CA 94304
Otello Stampacchia director, 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
John C Martin director 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Elena Ridloff director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130